GATC Biotech Releases Future Oriented Portfolio Structure

The Executive Board of GATC Biotech AG has introduced the new structure of its portfolio: Three operating divisions named Sequencing Solutions, Customized Solutions, and Diagnostic Solutions will build the solid base. This will give a far greater entrepreneurial independence, will allow a more targeted management of GATC Biotech’s respective businesses, positioning their solutions even closer to their markets as well as customers and will bring further improvements in efficiency. Further details of the new structure will be released during the coming months.

Peter Pohl, co-founder and CEO explained: “Through the reorganisation of the portfolio structure we will establish a better basis for a more differentiated management of our various businesses. This will increase our strategic flexibility and boost our leading competitive positions in different markets even better.” The business model for all three divisions is based on the provision of target-oriented and innovation-driven solutions. “We know that each research question is unique. So we try to address our customer’s needs in the most specific way.” added Peter Pohl.

Sequencing Solutions comprises our well-established Sanger sequencing services with our standardised and streamlined InViewTM products and is principally characterised by integrated technology platforms and utmost efficiency. The standardised products are complemented by the newly released modular NGSelectTM product line for GATC Biotech´s power user. For the majority of sequencing projects our standard solutions will meet all requirements.

Customized Solutions commits for individual projects - made-to-order for specific requirements not covered by standardised workflows.

Diagnostic Solutions targets for strong partnerships in the regulated market of human diagnostics. The ISO17025 accredited ‘Genome and Diagnostic Centre’ offers individual approaches in translational medicine for the development of companion diagnostics and the progressing implementation of personalised medicine in oncology.

GATC Biotech will further increase efficiency and effectiveness in order to strengthen their competitive advantages. In the future, investments and, where appropriate, alliances should further concentrate on securing and extending its stable market positions.

“Our strategy will be an unambiguous commitment to concentrate our efforts and resources on our priority areas of growth. I am confident that we made the right strategic decisions for continuous growth and to prove ourselves as an innovative scientific leader, and I’m equally confident that our GATC team possesses the expertise, determination and focus to deliver for our customers as well as our partners.” added Dr. Marcus Benz, COO.